Zobrazeno 1 - 10
of 276
pro vyhledávání: '"Kaoru, Tsuchiya"'
Autor:
Masatoshi Kudo, Kaoru Tsuchiya, Tatsuya Yamashita, Hironori Koga, Yuki Nakagawa, Masafumi Ikeda
Publikováno v:
Liver Cancer (2024)
Externí odkaz:
https://doaj.org/article/df97b2712f874e41b26657e7d8398087
Autor:
Nobuharu Tamaki, Mayu Higuchi, Taisei Keitoku, Yudai Yamazaki, Naoki Uchihara, Keito Suzuki, Yuki Tanaka, Haruka Miyamoto, Michiko Yamada, Risa Okada, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Yutaka Yasui, Kaoru Tsuchiya, Hiroyuki Nakanishi, Tatsuya Kanto, Masayuki Kurosaki, Namiki Izumi
Publikováno v:
JGH Open, Vol 8, Iss 4, Pp n/a-n/a (2024)
Abstract Background and Aim Magnetic resonance elastography (MRE) is used for the evaluation of liver fibrosis; however, it remains unclear whether MRE‐based liver stiffness is associated with hepatocellular carcinoma (HCC) development, particularl
Externí odkaz:
https://doaj.org/article/00b6fa8436ce46a8989df0a08634e2b5
Autor:
Shun Ishido, Nobuharu Tamaki, Naoki Uchihara, Keito Suzuki, Yuki Tanaka, Haruka Miyamoto, Michiko Yamada, Hiroaki Matsumoto, Tsubasa Nobusawa, Taisei Keitoku, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Yutaka Yasui, Yuka Takahashi, Kaoru Tsuchiya, Hiroyuki Nakanishi, Jun Itakura, Masayuki Kurosaki, Namiki Izumi
Publikováno v:
JGH Open, Vol 7, Iss 8, Pp 567-571 (2023)
Abstract Background and Aim Hepatocellular carcinoma development can be decreased by achieving and maintaining complete virological response (CVR) in chronic hepatitis B. However, it is unclear whether switching from entecavir (ETV) to tenofovir alaf
Externí odkaz:
https://doaj.org/article/2a2f83f241f647a78232eee83eec28f4
Autor:
Shun Ishido, Nobuharu Tamaki, Yuka Takahashi, Naoki Uchihara, Keito Suzuki, Yuki Tanaka, Haruka Miyamoto, Michiko Yamada, Hiroaki Matsumoto, Tsubasa Nobusawa, Taisei Keitoku, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Yutaka Yasui, Kaoru Tsuchiya, Hiroyuki Nakanishi, Masayuki Kurosaki, Namiki Izumi
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-6 (2023)
Abstract Background Patients with nonalcoholic fatty liver disease (NAFLD) are highly at risk for cardiovascular disease (CVD). However, the risk of developing CVD in patients with lean NAFLD is not yet fully understood. Therefore, this study aimed t
Externí odkaz:
https://doaj.org/article/196387580c6b4457bdf5411a8fa1646d
Autor:
Nobuharu Tamaki, Kenta Takaura, Mayu Higuchi, Yutaka Yasui, Jun Itakura, Kaoru Tsuchiya, Hiroyuki Nakanishi, Namiki Izumi, Masayuki Kurosaki
Publikováno v:
Diagnostics, Vol 14, Iss 13, p 1317 (2024)
Background and aims: The enhanced liver fibrosis (ELF) score is a blood test that combines three markers linked to liver fibrosis. The utility of the ELF score has been demonstrated primarily in Western countries, but whether it is useful in areas wi
Externí odkaz:
https://doaj.org/article/5bb761a4c93d4e739743dc8b49692db0
Autor:
Koji Yamashita, Masayuki Kurosaki, Hiroyuki Nakanishi, Yuki Tanaka, Shun Ishido, Kento Inada, Sakura Kirino, Yuka Hayakawa, Hiroaki Matsumoto, Tsubasa Nobusawa, Tatsuya Kakegawa, Mayu Higuchi, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Shun Kaneko, Nobuharu Tamaki, Yutaka Yasui, Kaoru Tsuchiya, Yuka Takahashi, Ryoichi Miyazaki, Takashi Ashikaga, Nobuyuki Enomoto, Namiki Izumi
Publikováno v:
JGH Open, Vol 6, Iss 11, Pp 774-781 (2022)
Abstract Aims Portopulmonary hypertension (PoPH) is a subtype of pulmonary arterial hypertension related to portal hypertension. The definitive diagnosis of PoPH is made by invasive right heart catheterization. Alternatively, pulmonary arterial hyper
Externí odkaz:
https://doaj.org/article/4a52742d455c41f19ef4407435667969
Autor:
Shun Ishido, Nobuharu Tamaki, Kento Inada, Jun Itakura, Yuka Takahashi, Naoki Uchihara, Keito Suzuki, Yuki Tanaka, Haruka Miyamoto, Michiko Yamada, Hiroaki Matsumoto, Tsubasa Nobusawa, Taisei Keitoku, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Yutaka Yasui, Kaoru Tsuchiya, Hiroyuki Nakanishi, Masayuki Kurosaki, Namiki Izumi
Publikováno v:
Clinical Case Reports, Vol 11, Iss 7, Pp n/a-n/a (2023)
Key Clinical Message The liquid CGP was useful for detecting FGFR2 fusion and the patient experienced typical side effects (nail disorders, hyperphosphatemia, and taste disorders) of pemigatinib that required treatment.
Externí odkaz:
https://doaj.org/article/858567e6ea0540f5ab70e1b775051c30
Autor:
Shun Kaneko, Kaoru Tsuchiya, Yutaka Yasui, Yuki Tanaka, Kento Inada, Shun Ishido, Sakura Kirino, Koji Yamashita, Yuka Hayakawa, Tsubasa Nobusawa, Hiroaki Matsumoto, Tatsuya Kakegawa, Mayu Higuchi, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Nobuharu Tamaki, Yuka Takahashi, Hiroyuki Nakanishi, Takumi Irie, Shun‐Ichi Ariizumi, Masayuki Kurosaki, Namiki Izumi
Publikováno v:
JGH Open, Vol 6, Iss 5, Pp 301-308 (2022)
Abstract Background and Aim Conversion surgery (CS), which aims to cure after systematic therapy, is only scarcely reported in the field of hepatocellular carcinoma (HCC). However, advancements in systemic therapy for HCC are expected to increase the
Externí odkaz:
https://doaj.org/article/896f5a83aa354941b6e45e2c416ab912
Autor:
Masatoshi Kudo, Kaoru Tsuchiya, Yu-Yun Shao, Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Tatsuya Yamashita, Hironori Koga, Ryosuke Take, Kyoko Yamada, Takashi Asakawa, Yuki Nakagawa, Masafumi Ikeda
Publikováno v:
Liver Cancer, Pp 1-1 (2023)
Introduction: The phase III IMbrave150 study established atezolizumab + bevacizumab as the global standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis examined the impact of bevacizumab interruption
Externí odkaz:
https://doaj.org/article/6af5eea42a484415bfabf884579086db
Autor:
Masatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, Kaoru Tsuchiya, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Naoshi Nishida, Chikara Ogawa, Tetsu Tomonari, Noriaki Nakamura, Hidekatsu Kuroda, Atsushi Takebe, Yoshifumi Takeyama, Masaaki Hidaka, Susumu Eguchi, Stephen L Chan, Masayuki Kurosaki, Namiki Izumi
Publikováno v:
Liver Cancer (2023)
Introduction: Atezolizumab plus bevacizumab therapy is extremely effective in the treatment of intermediate-stage hepatocellular carcinoma (HCC), with a response rate of 44%, as reported in the IMbrave150 trial. When tumor shrinkage is obtained, achi
Externí odkaz:
https://doaj.org/article/332e0f13cacf47a9aac3a9b2a4a83f4a